Background
==========

In clinical practice, cases of maternal or fetal distress necessitate immediate induction of labor. Prostaglandins (PGs) from the E and F series are the main promoters of cervical ripening and myometrial contractility. The influence of PG-E~2~in promotion of cervical maturation and uterine vasodilatation has been suggested as the primary functions of PGs in human parturition \[[@B1]\]. Local treatment with PG-E~2~gel is efficient for cervical priming \[[@B1],[@B2]\]. Prolonged pregnancy ≥ 42+0 gestational weeks occurs in 5-12% of pregnancies, predominantly in nulliparous women, exerting increased risks for perinatal mortality and morbidity \[[@B3]-[@B5]\]. Prolonged pregnancy is a key indication for cervical priming and induction of labor. The uterine cervix effaces towards the internal os and increases in diameter during the latency phase of labor, and it opens beyond 3-4 cm during the active phase. Late cervical ripening resembles an inflammatory reaction \[[@B1],[@B6],[@B7]\]. Progesterone, testosterone and cortisol are known to have anti-inflammatory properties \[[@B1],[@B8],[@B9]\].

Progesterone withdrawal associated with human parturition is characterized by decreased levels of the total progesterone receptor (PR) and an increased ratio of the inhibitory PR-A isoform to PR-B isoform form in the uterine cervix and myometrium \[[@B10]-[@B12]\].

The aim of this study was to evaluate the impact of PG-E~2~priming on the expression of the PR, androgen (AR) and glucocorticoid (GR) receptors in human uterine cervix in prolonged pregnancy. Serum levels of the receptor ligands, sex hormone-binding globulin (SHBG), and cervical expression of the prostaglandin synthase enzymes constitutive cyclooxygenase (COX)-1 and inducible COX-2 were also determined.

Methods
=======

Study patients
--------------

Ethics committee approval was obtained before the study (Karolinska University Hospital Ref No. 99-099). All women were healthy, non-smoking, had uncomplicated pregnancies, were without medication and gave informed consent to participate in the study. The study groups were nulliparous women with unripe cervices defined as a Bishop score ≤ 5 points. A Bishop score of ≥ 6 points was the criterion for a ripe cervix according to clinical guidelines \[[@B13]\]. The subjects were treated with PG-E~2~in viscous gel (Minprostin^®^Pharmacia, Sweden) for cervical priming and labour induction in postterm pregnancy ≥ 42+0 gestational weeks (Table [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}).

###### 

Clinical data controls.

  **Age**   **Gest age**   **Oxytocin**   **Anaesthesia**   **Weight**   **Gender**
  --------- -------------- -------------- ----------------- ------------ ------------
  27        37+5           \+             EDA               3190         M
  37        39+6           \+             EDA               3965         M
  30        39+4           \+             EDA               3280         M
  34        40+3           \+             EDA               3625         M
  21        37+0           \+             EDA               2595         F
  29        40+3           \+             EDA               3665         F
  20        40+5           \+             EDA               3815         F
  23        40+6           \+             EDA               3065         M
  30        39+3           \+             EDA               3130         M
  32        41+1           \+             EDA               3420         M
  32        40+5           \+             N~2~O             4175         M
  28        39+5           \+             EDA               3470         M
  31        40+1           \+             EDA               3590         F
  26        40+4           \+             EDA               3390         F
  31        40+1           \+             N~2~O             3540         M
  27        39+3           \+             EDA               2970         M
  26        41+0           \+             EDA               2815         F
  36        38+6           \+             EDA               4055         M
  37        40+5           \+             EDA               4130         F
                                                                         
  **30**    **39+6**       **19/19**      **17/19**         **3470**     **F7/M12**

Oxytocin = infusion of oxytocin10 U/glucose 2,5% 500 mL for augmentation of labor. EDA = epidural anaesthesia, N~2~O = inhalation of nitrous oxide 50%/oxygen 50%.

###### 

Clinical data responders.

  **Age**   **Gest age**   **BS**   **PG-E**   **Oxytocin**   **Anaesthesia**   **Weight**   **Gender**
  --------- -------------- -------- ---------- -------------- ----------------- ------------ ------------
  21        42+5           2        4          \+             EDA               3410         F
  31        42+4           2        7          \+             EDA               4360         M
  39        42+2           3        0,5        \+             EDA               2870         F
  28        42+3           4        4          \+             EDA               3960         F
  31        42+2           4        2          \+             EDA               3815         F
  37        42+5           0        4          \+             EDA               3535         F
  35        42+5           2        2          \+             EDA               4010         M
  21        42+4           4        2          \+             N~2~O, EDA        3430         M
  29        42+3           4        4          \+             N~2~O, EDA        3625         M
  28        42+1           2        2          \+             EDA               4245         M
  23        42+4           3        2          \+             EDA               3540         M
  30        42+1           4        4          \+             EDA               3985         M
                                                                                             
  **30**    **42+4**       **3**    **3,1**    **12/12**      **12/12**         **3732**     **F5/M7**

BS = Bishop score (points) before priming, PG-E~2~= accumulated PG-E~2~dose (mg), Oxytocin = infusion of oxytocin10 U/glucose 2,5% 500 mL for induction of labor. EDA = epidural anaesthesia, N~2~O = inhalation of nitrous oxide 50%/oxygen 50%.

###### 

Clinical data non-responders.

  **Age**   **Gest age**   **BS**   **PG-E**   **Oxytocin**   **Anaesthesia**   **Weight**   **Gender**
  --------- -------------- -------- ---------- -------------- ----------------- ------------ ------------
  32        42+4           2        6          \-             EDA               3730         F
  24        42+3           2        2          \+             EDA               2830         F
  31        42+3           2        5          \+             SPA               3565         F
  29        42+6           0        5,5        \-             SPA               5130         M
  26        42+5           0        4          \-             SPA               3960         F
  33        42+4           2        6          \+             SPA               2905         M
  29        42+4           2        6          \+             EDA               3630         F
  28        42+5           3        6          \+             EDA               4180         M
  37        42+4           3        1          \+             SPA               5060         M
  32        42+6           2        6,5        \+             SPA               4930         M
                                                                                             
  **30**    **42+4**       2        **4,7**    **7/10**       **10/10**         **3992**     **F5/M5**

BS = Bishop score (points) before priming, PG-E~2~= accumulated PG-E~2~dose (mg), Oxytocin = infusion of oxytocin10 U/glucose 2,5% 500 mL for induction of labor. EDA = epidural anaesthesia, SPA = spinal anaesthesia, N~2~O = inhalation of nitrous oxide 50%/oxygen 50%.

Nulliparous women (n = 18) with spontaneous onset of labor and vaginal partus at a normal gestational length served as a reference control (C) group. They had a median age of 30 years (range 20-37) a median gestational age of 39+6 weeks (range 37+0-41+1). Oxytocin infusion (Syntocinon^®^10 U/glucose 2,5% 500 mL) for augmentation of labor was administered to all women according to the clinical guidelines \[[@B14]\].

The responders (R) were nulliparous women (n = 12) who delivered vaginally after successful cervical priming with PG-E~2~. They had a median age of 30 years (range 21-39), a median gestational length of 42+4 weeks (range 42+1- 42+5) at partus, and median Bishop score of 3 points (range 0-4) at admission. All 12 women received oxytocin infusion for augmentation of labor.

The non-responders (NR) were nulliparous women (n = 10) who failed to enter the active phase of labor after treatment with PG-E~2~and therefore delivered by cesarean section \[[@B15]\]. They had a median age of 30 years (range 24-37), a median gestational length of 42+4 weeks (range 42+1- 42+6) at partus, and a median Bishop score of 2 points (range 0-4) before PG-E~2~treatment. Oxytocin infusion was administered to 7 of 10 women for induction of labor.

It was not possible to obtain a peripheral venous sample from every subject, due to practical reasons or lack of consent. The limited size of the cervical biopsies did not allow for analysis of both mRNA and immunohistochemistry (IHC) in all samples. Thus, the actual number for the mRNA analyses is given in the Results section.

Sampling procedure
------------------

The cervical biopsies were obtained transvaginally from the anterior part of the uterine cervix at the 12 o\'clock position, from 10-20 mm depth within 30 min after delivery. The biopsies were divided and one half was immersion-fixed in 4% formaldehyde overnight, stored at 4°C in 70% ethanol and thereafter embedded in paraffin. The other half was immediately frozen at -70°C. Cervical tissue obtained from women after partus at a normal gestational length served as reference material.

Serum analyses
--------------

Peripheral venous samples were drawn immediately after parturition or at cesarean section. They were centrifuged at 3000 × G for 10 min and stored at -20 °C until analyzed.

Serum levels of progesterone and SHBG were determined by direct chemiluminiscence enzyme immunoassay using commercially available kits from Diagnostic Products Corp., Los Angeles, CA (Immulite^®^). Serum testosterone was determined by direct radioimmunoassay using a kit obtained from Diagnostic Products Corp. (\"Coat-a-Count^®^\"). Serum 5α-DHT was determined after destruction of cross reacting testosterone by oxidative cleavage of the 4-ene double bond with potassium permanganate followed by extraction, using a kit from Diagnostic Systems Laboratories Inc., Webster, Texas, U.S.A. Values obtained by this method were compared with those obtained by a method including extraction with diethyl ether, column chromatography on celite and subsequent radioimmunoassay and an excellent correlation was found \[[@B16]\]. Circulating progesterone binds in \< 1%, testosterone in 70%, and its active metabolite 5α-dehydrotestosterone (DHT) in 28%, by high affinity to sex hormone-binding globulin (SHBG) \[[@B17]\]. The free androgen index (FAI) (total T/SHBG × 100) was calculated since the non SHBG-bound fraction is the biologically active fraction of steroid hormones \[[@B18]\].

RNA preparation and reverse transcription
-----------------------------------------

Total RNA from frozen cervical tissue samples was purified with the RNeasy^®^kit (Qiagen GmbH, Hilden, Germany) according to a procedure for RNA isolation from fibrous tissues, including a DNase step, as recommended by the manufacturer. Two μg of total RNA from each sample was reverse transcribed at 37°C for 60 min in a final volume of 30 μl with a reaction mixture (Qiagen) containing 1 × RT buffer, dNTP mix (0.5 mM each dNTP), 600 ng random primers (Invitrogen, Paisley, UK), 10 units RNase inhibitor (Superase-In, Ambion, Austin, TX), and 4 U of Omniscript™ reverse transcriptase (Qiagen).

Real time PCR analysis
----------------------

The oligonucleotide primers for PR-AB, PR-B, AR and Cyclophilin A are presented in Table [4](#T4){ref-type="table"}, as well as their predicted sizes. Real time PCR was performed in a DNA Engine Opticon™ 2 System (MJ Research, Waltham, MA). For PCR, the cDNAs corresponding to 40-100 ng (see Table [2](#T2){ref-type="table"}) RNA were added to 10 μl of Quantitect™ SYBR^®^Green PCR mix (Qiagen) containing HotStarTaq DNA polymerase, PCR buffer, dNTP mixture and 0.3 μM of each oligonucleotide primer in a final volume of 20 μl. The reactions were performed in opaque white 0.2 ml low-profile strip tubes sealed with optical flat caps (TLS-0851, TCS-0803, MJ Research). After initial incubation for 15 min at 95°C, the samples were subjected to 40-44 cycles of 10 s at 94°C, 15-20 s at 56°C (see Table [4](#T4){ref-type="table"}) and 20 s at 72°C with a final extension step at 72°C for 5 min. All PCR assays were performed twice. The purity of PCR products was confirmed by a melting curve analysis in all experiments (data not shown). All primers were designed to span an intron/exon boundary or to flank an intron. Thus, amplification of contaminating DNA was eliminated. Each PCR assay included a negative control containing a RNA sample without reverse transcription. The primers were based on the sequences of the human genes. The primer pairs (Table [4](#T4){ref-type="table"}) were designed with Primer3 software \[[@B19]\].

###### 

Oligonucleotide primers used for real-time PCR.

  ------------------------------------------------------------------------------------------------------------------------------
  **Gene**        **Accession No**              **Primers**\                   **Position**      **cDNA**   **Annealing step**
                                                **F = forward; R = reverse**                                
  --------------- ----------------------------- ------------------------------ ----------------- ---------- --------------------
  PRAB            [NM_000926.4](NM_000926.4)\   F: tggaagaaatgactgcatcg\       bp 2555-2574\     40 ng      56°C/15 s
                  \[[@B37]\]                    R: agcatccagtgctctcacaa        bp 2702-2683\                
                                                                               product: 148 bp              

  PRB             [NM_000926.4](NM_000926.4)\   F: gactgagctgaaggcaaagg\       bp 746-765\       40 ng      56°C/15 s
                  \[[@B37]\]                    R: cgaaacttcaggcaaggtgtc       bp 890-870\                  
                                                                               product: 145 bp              

  AR              [NM_000044.2](NM_000044.2)    F: taccagctcaccaagctcct\       bp 3687-3706\     100 ng     56°C/20 s
                                                R: gcttcactgggtgtggaaat        bp 3882-3861\                
                                                                               product: 195 bp              

  Cyclophilin A   [NM_021130.3](NM_021130.3)    F: gtggtgtttggcaaagtgaa\       bp 462-481\       40 ng      56°C/20 s
                                                R: tcgagttgtccacagtcagc        bp 577-558\                  
                                                                               product: 116 bp              
  ------------------------------------------------------------------------------------------------------------------------------

Quantification of mRNA
----------------------

To standardize the quantification method, cyclophilin A was selected as the housekeeping gene. The PCR amplification rate and the cycle threshold (Ct) values were analyzed using Opticon Monitor 3.0 software (MJ Research). The values of relative expression of genes of interest were normalized against the cyclophilin A product.

Immunohistochemical analysis
----------------------------

Immunostaining for the determination of PR-AB, PR-A, PR-B, AR, GR, COX-1 and COX-2 utilizing the avidin-biotin peroxidase complex (ABC) procedure was performed \[[@B20]\]. The 5 μm paraffin sections prepared from cervical biopsies were first dewaxed in Bioclear (Bio-Optica, Milan, Italy), rehydrated and washed with phosphate-buffered saline (PBS; pH 7.4). Thereafter the sections were subjected to microwave antigen retrieval in 0.01 M sodium citrate buffer (pH 6.0) for 10 min and then allowed to cool for 20 min. Subsequently, endogenous peroxidase activity was quenched by immersion in 3% hydrogen peroxide (Merck) in methanol for 10 min at room temperature (RT); followed by blocking non-specific binding of the primary antibody by incubation as shown in Table [5](#T5){ref-type="table"}, at RT. The sections were then incubated with the primary antibodies (see Table [5](#T5){ref-type="table"}). For the negative controls the primary antibody was replaced by mouse IgG (or in the case of GR rabbit IgG, and for COX-1 and -2 goat IgG) at a corresponding concentration to the antibody it replaced.

###### 

Antibodies used in the study.

  **Protein**   **Primary ab, company and order number**   **Type and dilution**         **Inc temp + time**   **Blocking**   **Biotinylated 2 nd Ab all diluted 1:200**   **Buffer**        **Inc time in RT**
  ------------- ------------------------------------------ ----------------------------- --------------------- -------------- -------------------------------------------- ----------------- --------------------
  PRAB          Zymed Lab Inc, 18-0172                     Mc mouse anti human 1:150     RT 60 min             1.5% NHS       horse anti-mouse                             1.5% NHS in PBS   45 min
  PRA           Novocastra Labs Ltd, NCL-PGR312            Mc mouse anti human 1:500     RT 60 min             1.5% NHS       horse anti-mouse                             1.5% NHS in PBS   45 min
  PRB           Affinity BioReagents Inc, MA1-411          Mc mouse Anti chick 1:100     RT 60 min             1.5% NHS       horse anti-mouse                             1.5% NHS in PBS   45 min
  AR            DakoCyto-mation Inc, M3562                 Mc mouse anti human 1:100     +4°C o/n              2% NHS         horse anti-mouse                             2% NHS in PBS     30 min
  GR            Affinity Bio Reagents Inc, PA1-511A        Pc rabbit anti human 1:1000   +4°C o/n              2% NGS         goat anti rabbit                             2% NGS in PBS     60 min
  COX-1         Santa Cruz Biotechnology Inc, sc 1752      Pc goat anti human 1:100      +37°C 60 min          10% NRS        rabbit anti goat                             10% NRS in PBS    30 min
  COX-2         Santa Cruz Biotechnology Inc, sc 1745      Pc goat anti human 1:100      +37°C 60 min          10% NRS        rabbit anti goat                             10% NRS in PBS    30 min

Mc = monoclonal, Pc = polyclonal

RT = room temperature

biotinylated horse anti-mouse (Vector, Cat\# BA-2000)

biotinylated goat anti rabbit (Vector, Cat\# BA-1000)

biotinylated rabbit anti goat (Vector, Cat\# BA-5000)

The secondary biotinylated antibodies were incubated as shown in Table [5](#T5){ref-type="table"}, followed by incubation with an avidin-biotin horseradish peroxidase complex (Vectastain Elite, Cat\# PK-6100) for 30 min at RT. The site of the bound enzyme was visualized by the application of 3,3\'-diaminobenzidine (DAB kit, Vector, CA), a chromogen which produces a brown, insoluble precipitate when incubated with enzyme. The sections were counterstained with haematoxylin and dehydrated before they were mounted with Pertex (Histolab, Gothenburg).

Image analysis
--------------

A Leica microscope and Sony video camera (Park Ridge, NJ, U.S.A.) connected to a computer with an image analysis system (Leica Imaging System Ltd, Cambridge, UK) was used to assess quantitative values from immunohistochemistry. The quantification of immunostaining was performed as described previously \[[@B20]\]. In short, by using colour discrimination software the total area of positively stained nuclei was measured, and expressed as a ratio of the total area of cell nuclei.

Manual scoring
--------------

Two observers blinded to the identity of the slides performed all the assessments. The staining was evaluated semi-quantitatively using a grading system. The staining intensity was graded on a scale of (0) no staining, (1) faint, (2) moderate or (3) strong staining.

Statistical analyses
--------------------

Clinical data were calculated with ANOVA/ANCOVA and significances were evaluated with Scheffe\'s test. Statistical calculation for serum hormone levels, receptor and mRNA levels was performed by ANOVA on ranks (Kruskal-Wallis test) and significances were evaluated by Dunn\'s test. Values with different letter designations are significantly different at level p \< 0.05.

Results
=======

Clinical data
-------------

The median maternal age and fetal gender did not differ between the groups. The neonatal weights were, as was expected, significantly higher in the postterm NR and R groups as compared to term C group (p \< 0.05).

Serum levels of steroid hormones and SHBG
-----------------------------------------

No differences were observed for progesterone, total testosterone, 5α-DHT levels or FAI between C (n = 16), R (n = 8) and NR (n = 8) groups. Serum progesterone (medians and range) was 299 (175-563) nmol/L in C, 220 (115-394) in R, and 234 (159-423) in NR. Serum testosterone was 3.06 (1.07-7.84) nmol/L in C, 3.42 (1.72-4.47) in R, and 2.93 (2.13-7.81) in NR. Serum 5α-DHT was 1.02 (0.04-2.42) nmol/L in C, 0.96 (0.57-1.18) in R, and 0.77 (0.58-1.22) in NR. Serum SHBG was significantly lower 301 (248-424) nmol/L in NR (n = 7), as compared to C 512 (304-708) and R 504 (236-644), whereas the FAI (T/SHBG × 100) was comparable between the groups 0.556 (0.187-2.56) in C, 0.770 (0.352-1.75) in R, and 0.834 (0.634-2.60) in NR.

mRNA levels
-----------

The PR-AB mRNA level was lower in responders as compared to the non-responders. The ratio between PR-AB and PR-B represents the PR-A mRNA level which did not change between the groups (Figure [1](#F1){ref-type="fig"}, upper middle panel). The PRB mRNA showed similar results as the PR-AB mRNA, but differences between groups did not reach significance. The AR mRNA level showed a tendency to be increased in the NR group, but did not reach significance (Figure [1](#F1){ref-type="fig"}, bottom panel).

![**Real-time PCR results for expression of PR-AB (upper), PR-AB/PR-B (upper middle), PR-B (lower middle) and AR (bottom) mRNAs in human cervix from the C (n = 11), R (n = 10) and NR (n = 4) groups respectively**. The values of relative expression of target genes were normalized against cyclophilin A and displayed in arbitrary units. The ratio of PR-AB/PR-B represents the PR-A expression. The \"box-and-whisker plot\" represents the median value with 50% of all data falling within the box. The whiskers extend to the 5th and 95th percentiles. Boxes with different letter designations are significantly different, p \< 0.05.](1477-7827-7-116-1){#F1}

Immunohistochemistry
--------------------

The immunohistochemistry (IHC) scores for nuclear PR-AB (top panel), PR-A (upper middle panel), PR-B (lower middle panel) and AR (bottom panel) protein are presented in Figure [2](#F2){ref-type="fig"} and representative images of the IHC results are shown in Figure [3](#F3){ref-type="fig"}.

![**Immunostaining results for PR-AB (top), PR-A (upper middle), PR-B (lower middle) and AR (bottom) in stroma, as assessed by image analysis in cervical samples from controls (C), responders (R) and non-responders (NR)**. The \"box-and-whisker plot\" represents the median value with 50% of all data falling within the box. The whiskers extend to the 5th and 95th percentiles. Boxes with different letter designations are significantly different, p \< 0.05.](1477-7827-7-116-2){#F2}

![**Representative images of the immunostaining results for PR-AB (A-C), PR-A (D-F), PR-B (G-I), AR (J-L), COX-1 (M), COX-2 (N) and GR (O)**. A negative control is shown for monoclonal antibodies (**P**) where the primary antibody was replaced by an equal amount of mouse IgG. The magnification bars represent 30 μm in all images.](1477-7827-7-116-3){#F3}

The IHC score for PR-AB was lower in responders as compared to non-responders (Figure [2](#F2){ref-type="fig"} top panel; Figure [3A-C](#F3){ref-type="fig"}). The IHC score for PR-B was lower in responders as compared to controls (Figure [2](#F2){ref-type="fig"} lower middle panel; Figure [3G-I](#F3){ref-type="fig"}). The IHC score for PR-A did not differ between study groups.

Immunohistochemical analysis revealed a significantly lower AR expression in the responders as compared to non-responders and controls (Figure [2](#F2){ref-type="fig"} bottom panel; Figure [3J-L](#F3){ref-type="fig"}).

The IHC scores for stromal COX-1, COX-2 and GR did not differ between groups (data not shown). Representative images from immunostaining of COX-1 (M), COX-2 (N) and GR (O) are shown in Figure [3](#F3){ref-type="fig"} as well as a negative control (P) where the primary antibody was replaced by an equal amount of mouse IgG.

Discussion
==========

Prolonged pregnancy constitutes a key indication for cervical priming and induction of labor \[[@B3]-[@B5]\]. Local treatment with PG-E~2~gel has been shown to promote degradation of the extracellular matrix by increasing matrix metalloproteinase (MMP)-1 collagenase activity and by altering the proteoglycan content \[[@B2],[@B21],[@B22]\]. Prostaglandin-E~2~was reported to induce a functional progesterone withdrawal *in vitro*by increasing the inhibitory PR-A over PR-B expression through the protein kinase (PK)-C pathway in a human myometrial cell line (PHM1-31) \[[@B23]\].

We found that serum levels of the receptor ligands were unchanged between the groups. However, the responder group displayed a lower cervical level of total PR-AB protein as compared to non-responders, and a lower cervical PR-B isoform level as compared to controls. The PR mRNA level was lower in responders as compared to non-responders, whereas no difference was found for the inhibitory PR-A isoform, which acts as a repressor of the PR-B isoform and other steroid receptors such as AR and GR \[[@B24]\]. Thus, decreased PR-AB and PR-B protein levels in responders indicate that PG-E~2~priming leading to vaginal partus was associated with a nuclear PR withdrawal. The decreased PR-AB level in responders as compared to non-responders could be the consequence of a vaginal delivery. Nevertheless, the decreased PR-B level in responders as compared to controls cannot be explained by a different mode of delivery. Furthermore, PG-E~2~promotes chemotaxis in neutrophils and macrophages, which enhances leukocyte extravasation into tissues by a synergistic action with chemotactic interleukin (IL)-8 \[[@B1],[@B25],[@B26]\]. This is in accordance with the high leukocyte density and immunostaining for IL-8 observed in responders \[[@B27]\]. Pro-inflammatory cytokines activate the key pro-inflammatory transcription factor nuclear factor (NF)-κB, which was shown to exert a mutual negative interaction with PR \[[@B8],[@B28]\]. The comparable levels of COX-2 between the groups could be explained by the oxytocin treatment, since oxytocin initiates COX-2 gene transcription \[[@B29]\]. In addition, mechanical stretch induces COX-2 activity \[[@B30]\].

Since the cervical AR protein level was lower in responders not only as compared to non-responders who delivered by cesarean sections, but also as compared to controls who delivered spontaneously, the result cannot be explained by a different mode of delivery. The low AR protein level in responders indicates that successful PG-E~2~priming was followed by an androgen withdrawal at the receptor level. This finding is in accordance with results from *in vitro*studies, in which androgens were reported to attenuate the synthesis of pro-inflammatory cytokines, inhibit MMP-1 production and regulate cervical resistance by altering the proteoglycan content \[[@B31]-[@B34]\]. Possible responses to the androgen withdrawal reported here could therefore be events leading to degradation of the extracellular matrix and cervical maturation \[[@B21],[@B22],[@B32]\].

Comparing the results of mRNA and protein for PR-AB, PR-A, PR-B and AR, all showed a similar expression pattern, although only PR-AB displayed significant changes for both mRNA and protein. The lack of significance for mRNA levels of PR-B and AR could be due to the fact that mRNA levels were detected in cervix tissue homogenate whereas the protein levels were determined in stromal nuclei.

The total GR protein level in human uterine cervical stroma and squamous epithelium was decreased after term labor as compared to late pregnancy \[[@B35]\], but no differences were found between the groups in the present study.

In conclusion, successful local PG-E~2~treatment for cervical priming after prolonged pregnancy was correlated to a progesterone and androgen withdrawal at the receptor level. A comparable progesterone and androgen withdrawal was neither observed in the non-responders, who failed to enter the active phase of labor and underwent cesarean sections, nor in the term control group with spontaneous deliveries. The progesterone withdrawal is in accordance with the previous study \[[@B36]\], whereas the possibility of an androgen withdrawal, to our knowledge, has not been reported previously. We conclude that successful PG-E~2~priming was followed by a functional progesterone and androgen withdrawal at the receptor level in the uterine cervix. It is possible that treatment with an antiprogestin or an antiandrogen could serve as a supplement to PG-E~2~priming in non-responders.
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